United Therapeutics Corporation Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $126.30M, a 597.79% increase year-over-year.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $68.30M, a 311.45% increase year-over-year.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $99.00M, a 283.72% increase year-over-year.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $40.20M, a 23.69% increase year-over-year.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for fiscal 2025 was $173.90M, a 13.96% increase from fiscal 2024.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for fiscal 2024 was $152.60M, a 55.71% increase from fiscal 2023.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for fiscal 2023 was $98.00M, a 10.86% increase from fiscal 2022.
- United Therapeutics Corporation stock issued during period, value, stock options exercised for fiscal 2022 was $88.40M, a 76.80% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $126.30M 10-Q · filed 2026-08-05 | $333.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $68.30M 10-Q · filed 2026-05-06 | $225.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $173.90M 10-K · filed 2026-02-25 |
| 2025-09-30 | $40.20M 10-Q · filed 2025-10-29 | $100.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $18.10M 10-Q · filed 2026-08-05 | $93.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.60M 10-Q · filed 2026-05-06 | $127.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $25.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $152.60M 10-K · filed 2026-02-25 |
| 2024-09-30 | $32.50M 10-Q · filed 2025-10-29 | $134.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $52.10M 10-Q · filed 2025-07-30 | $106.20M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $42.20M 10-Q · filed 2025-04-30 | $78.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $98.00M 10-K · filed 2026-02-25 |
| 2023-09-30 | $4.60M 10-Q · filed 2024-10-30 | $146.20M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $24.70M 10-Q · filed 2024-07-31 | $146.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $61.40M 10-Q · filed 2024-05-01 | $145.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $88.40M 10-K · filed 2025-02-26 |
| 2022-09-30 | $4.70M 10-Q · filed 2023-11-01 | $40.60M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $23.90M 10-Q · filed 2023-08-02 | $49.90M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $4.30M 10-Q · filed 2023-05-03 | $36.80M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $50.00M 10-K · filed 2024-02-21 |
| 2021-09-30 | $14.00M 10-Q · filed 2022-11-02 | $50.20M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $10.80M 10-Q · filed 2022-08-03 | $39.70M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $17.50M 10-Q · filed 2022-05-04 | $50.60M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $33.80M 10-K · filed 2023-02-22 |
| 2020-09-30 | $3.50M 10-Q · filed 2021-11-03 | $25.90M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $21.70M 10-Q · filed 2021-08-04 | $22.40M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $700.00K 10-Q · filed 2021-05-05 | $1.80M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $9.90M 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $10.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.10M 10-Q · filed 2020-07-29 | $10.60M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $8.80M 10-Q · filed 2020-04-29 | $15.20M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $15.60M 10-K · filed 2021-02-24 |
| 2018-09-30 | $600.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $5.70M 10-Q · filed 2019-07-31 | |
| 2018-03-31 | $9.20M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $39.90M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $7.70M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $39.30M 10-K · filed 2018-02-21 | |
| 2014-12-31 | $50.20M 10-K · filed 2017-02-22 | |
| 2013-12-31 | $26.62M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $16.80M 10-K · filed 2015-02-24 | |
| 2011-12-31 | $23.96M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $83.35M 10-K · filed 2013-02-26 | |
| 2009-12-31 | $32.07M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $41.94M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |